Spots Global Cancer Trial Database for Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
Official Title: A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Study ID: NCT02398058
Study Description
Brief Summary: This is a Phase 1b, multi-site, open-label, non-randomized clinical trial evaluating the safety, tolerability, and pharmacokinetics of escalating doses of olaparib and trabectedin in patients with unresectable advanced/metastatic sarcomas. Patients will continue to be treated on this combination regimen in the absence of disease progression, intolerable toxicity or patient's decision.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, , Italy
Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, , Italy
Contact Details
Name: Giovanni Grignani, MD
Affiliation: Italian Sarcoma Group
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
